FSSAI opens three adjudication cases against Nestlé India over infant-food claims
India’s food regulator has initiated three adjudication cases involving promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, alongside an allegation of sub-standard biotin content in a follow-up formula. No final penalty has been announced.
What happened
FSSAI initiated three adjudication cases against Nestle India over promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, and alleged sub-standard
Key facts
- Three separate adjudication cases
- Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020
- Section 3 of the Infant Milk Substitutes Act, 1992
Why this matters
Regulatory diligence for infant-nutrition assets in India should place greater weight on substantiation of marketing claims, labeling practices and formulation-compliance controls.
What to watch
- FSSAI adjudication notices, hearing dates, final orders and the size or nature of any penalties.
- Whether regulators order product recall, stop-sale, relabeling, corrective advertising or restrictions on specific Stage 1/follow-up formula SKUs.
- Additional sampling findings involving biotin or other nutrient-composition parameters.
- Evidence that the regulator expands reviews to other Nestlé India infant-food products or rival manufacturers.
- Changes in e-commerce listings, pharmacy availability, retailer ordering patterns and consumer complaint volumes.
- Nestlé India disclosures on provisions, inventory write-downs, sales effects or changes to infant-nutrition marketing.
- Audit and suspend or revise claims across NAN, Lactogen and adjacent infant-nutrition brands before adjudication outcomes.
- Increase batch testing, supplier verification and regulatory documentation for micronutrient specifications, especially biotin.
- Prepare retailer, distributor, pediatrician and consumer communications emphasizing product safety, corrective actions and continuity of supply.
- Build contingency plans for relabeling, withdrawal, replacement inventory and potential channel-level restrictions on the named products.
- Monitor legal options and engage FSSAI on corrective-action commitments that could limit escalation.